Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation

被引:1380
作者
Llovet, JM [1 ]
Fuster, J [1 ]
Bruix, J [1 ]
机构
[1] Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Catalonia, Spain
关键词
D O I
10.1002/hep.510300629
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Liver transplantation is proposed as the best therapy for early hepatocellular carcinoma in cirrhotic patients. However, the confrontation with the results obtained by surgical resection has never been done on an intention-to-treat basis. Between 1989 and 1997, 164 out of 1,265 patients with hepatocellular carcinoma were evaluated for surgery. Seventy-seven (48 men, mean 61 years of age, 74 Child-Pugh class A, size 33 +/- 18 mm) were resected (first line option) and 87 (65 men, mean 55 years of age, 50 Child-Pugh class B/C, size 24 +/- 14 mm) were selected for transplantation. The 1-, 3-, and 5-year "intention-to-treat" survival was 85%, 62%, and 51% for resection and 84%, 69%, and 69% for transplantation (8 drop-outs on waiting list). Bilirubin and clinically relevant portal hypertension were independent survival predictors after resection. Thereby, the 5-year survival of the best candidates (absence of clinically relevant portal hypertension, n = 35) was 74%, whereas it was 25% for the worst candidates (portal hypertension and bilirubin greater than or equal to 1 mg/dL, n = 27) (P < .00001). The variable "drop-out on waiting list" was the sole survival predictor after transplantation. The 2-year survival rate of patients evaluated for transplantation was 84% in the 1989 to 1995 period (mean waiting time, 62 days; no drop-outs) and 54% during 1996 to 1997 (mean waiting time, 162 days; 8 dropouts)(P < .003). This outcome was significantly lower than that of the best candidates for resection (P = .002). In conclusion, a proper selection of candidates for resection promotes better results than transplantation, in which the results are significantly hampered by the growing incidence of drop-outs because of the increasing waiting time.
引用
收藏
页码:1434 / 1440
页数:7
相关论文
共 45 条
[1]
Resection of hepatocellular carcinoma in patients with cirrhosis [J].
Balsells, J ;
Charco, R ;
Lazaro, JL ;
Murio, E ;
Vargas, V ;
Allende, E ;
Margarit, C .
BRITISH JOURNAL OF SURGERY, 1996, 83 (06) :758-761
[2]
INTRAHEPATIC RECURRENCE AFTER RESECTION OF HEPATOCELLULAR-CARCINOMA COMPLICATING CIRRHOSIS [J].
BELGHITI, J ;
PANIS, Y ;
FARGES, O ;
BENHAMOU, JP ;
FEKETE, F .
ANNALS OF SURGERY, 1991, 214 (02) :114-117
[3]
PRIMARY-TREATMENT OF HEPATOCELLULAR-CARCINOMA BY ARTERIAL CHEMOEMBOLIZATION [J].
BISMUTH, H ;
MORINO, M ;
SHERLOCK, D ;
CASTAING, D ;
MIGLIETTA, C ;
CAUQUIL, P ;
ROCHE, A .
AMERICAN JOURNAL OF SURGERY, 1992, 163 (04) :387-394
[4]
LIVER RESECTION VERSUS TRANSPLANTATION FOR HEPATOCELLULAR-CARCINOMA IN CIRRHOTIC-PATIENTS [J].
BISMUTH, H ;
CHICHE, L ;
ADAM, R ;
CASTAING, D ;
DIAMOND, T ;
DENNISON, A .
ANNALS OF SURGERY, 1993, 218 (02) :145-151
[5]
HEMODYNAMIC EVALUATION OF THE PATIENT WITH PORTAL-HYPERTENSION [J].
BOSCH, J ;
MASTAI, R ;
KRAVETZ, D ;
NAVASA, M ;
RODES, J .
SEMINARS IN LIVER DISEASE, 1986, 6 (04) :309-317
[6]
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma:: Results of a randomized, controlled trial in a single institution [J].
Bruix, J ;
Llovet, JM ;
Castells, A ;
Montañá, X ;
Brú, C ;
Ayuso, MD ;
Vilana, R ;
Rodés, J .
HEPATOLOGY, 1998, 27 (06) :1578-1583
[7]
PHASE-II STUDY OF TRANSARTERIAL EMBOLIZATION IN EUROPEAN PATIENTS WITH HEPATOCELLULAR-CARCINOMA - NEED FOR CONTROLLED TRIALS [J].
BRUIX, J ;
CASTELLS, A ;
MONTANYA, X ;
CALVET, X ;
BRU, C ;
AYUSO, C ;
JOVER, L ;
GARCIA, L ;
VILANA, R ;
BOIX, L ;
RODES, J .
HEPATOLOGY, 1994, 20 (03) :643-650
[8]
Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure [J].
Bruix, J ;
Castells, A ;
Bosch, J ;
Feu, F ;
Fuster, J ;
GarciaPagan, JC ;
Visa, J ;
Bru, C ;
Rodes, J .
GASTROENTEROLOGY, 1996, 111 (04) :1018-1022
[9]
Bruix J, 1997, HEPATOLOGY, V25, P259
[10]
TREATMENT OF HEPATOCELLULAR-CARCINOMA WITH TAMOXIFEN - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL IN 120 PATIENTS [J].
CASTELLS, A ;
BRUIX, J ;
BRU, C ;
AYUSO, C ;
ROCA, M ;
BOIX, L ;
VILANA, R ;
RODES, J .
GASTROENTEROLOGY, 1995, 109 (03) :917-922